Material Safety Data Sheet
ANSI Format

Anacin Products

Preparation Date 20-Aug-2007 **Revision Date** 31-Mar-2008 **Revision Number** 4

1. PRODUCT AND COMPANY IDENTIFICATION

Product Name	Anacin Products
Common Name	Not available
Chemical Name	Not applicable
Synonyms	Anacin Tablets, Anacin Aspirin Free, Anacin Extra Strength
Product Use	Pharmaceutical product
Classification	Antipyretic, Analgesic
Supplier	Wyeth P.O. Box 8299 Philadelphia, PA 19101 USA. Telephone: 1-610-688-4400
Emergency Telephone Number	Chemtrec USA, Puerto Rico, Canada 1-800-424-9300 Chemtrec International 1-703-527-3887

2. HAZARDS IDENTIFICATION

Emergency Overview

This contains an active pharmaceutical ingredient that can affect body functions; handle with caution.

Appearance Pharmaceutical Tablet , Caplet **Physical State** Solid **Odor** Not available

Potential Physical Hazards Powders and solids are presumed to be combustible.

Potential Health Effects

Eyes	Not available
Skin	Not available
Inhalation	Not available
Ingestion	The most common effects may include Reye's Syndrome, severe allergic reaction (hives, facial swelling, asthma (wheezing), shock), ringing in the ears, or loss of hearing. May affect the unborn child. Excreted in breast milk. Please see Patient Package Insert for further information.
Therapeutic Target Organ(s)	Systemic. Not listed by OSHA, NTP or IARC.

Potential Environmental Effects See Section 12.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Common Name	CAS-No	Composition
Acetaminophen	103-90-2	0-500 mg/tablet
Acetylsalicylate Acid	50-78-2	0-500 mg/tablet
Caffeine	58-08-2	0-32 mg/tablet
Inactive Ingredients	Not applicable	Remainder

4. FIRST AID MEASURES

Eye Contact In the case of contact with eyes, rinse immediately with plenty of water for 15 minutes and seek medical advice.

Skin Contact Take off contaminated clothing and shoes immediately. Wash off immediately with soap and plenty of water. If skin irritation persists, call a physician.

Inhalation Move to fresh air. Artificial respiration and/or oxygen may be necessary. If symptoms persist, call a physician.

Ingestion If symptoms persist, call a physician. Do not induce vomiting without medical advice. Never give anything by mouth to an unconscious person.

5. FIRE-FIGHTING MEASURES

Flammable Properties Presumed to be a combustible particulate solid.

Extinguishing Media

Suitable Extinguishing Media Use water spray, foam, dry chemical or carbon dioxide.

Unsuitable Extinguishing Media Do NOT use water jet.

Fire Fighting Evacuate area and fight fire from a safe distance. Cool closed containers exposed to fire with water spray. In the event of fire and/or explosion do not breathe fumes.

Hazardous Combustion Products Carbon oxides, nitrogen oxides.

Protective Equipment and Precautions for Firefighters In the event of fire, wear self-contained breathing apparatus and special protective equipment for fire fighters.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions Refer to protective measures listed in Sections 7 and 8.

Environmental Precautions Prevent product from entering drains. Local authorities should be advised if a significant spill cannot be contained.

Methods for Containment Not available

Methods for Cleaning up Take up mechanically and collect in suitable container for disposal. Clean contaminated surface thoroughly. Avoid formation of dust and aerosols.

7. HANDLING AND STORAGE

Handling For personal protection see Section 8. Handle in accordance with good industrial hygiene and safety practice. Skin should be washed after contact. Avoid formation of dust and aerosols.

Storage No special safety precautions required. Keep container tightly closed.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Common Name	**Exposure Guideline**
Inactive Ingredients	250 mg/m^3
Acetaminophen	2000 mcg/m^3
Acetylsalicylate Acid	750 mcg/m^3
Caffeine	500 mcg/m^3

Engineering Controls Apply technical measures to comply with the occupational exposure guideline. Local exhaust ventilation is needed for limited open handling or where aerosols may be generated.

Personal Protective Equipment

Eye/face Protection Provide eye protection based on risk assessment.

Skin Protection Wear nitrile or latex gloves. Wear protective garment.

Respiratory Protection Base respirator selection on a risk assessment.

General Hygiene Considerations When using, do not eat, drink or smoke. General industrial hygiene practice. Wash hands before breaks and at the end of workday.

Other Limit access to only personnel trained in the safe handling of this material. Consult a health and safety professional for specific PPE, respirator, and risk assessment guidance.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	Pharmaceutical Tablet , Caplet	**Physical State**	Solid
Color	Various	**Odor**	Not available
Odor Threshold	Not available		
pH	Not applicable		
Specific Gravity	Not applicable	**Water Solubility**	Not available
Solubility	Not applicable	**Evaporation Rate**	Not applicable
Partition Coefficient (n-octanol/water)	Not available	**Vapor Pressure**	Not applicable
Boiling Point	Not applicable	**Autoignition Temperature**	Not applicable
Flash Point	Not applicable	**Method**	None
Melting Point	Not available		
Flammability Limits in Air	**Upper** Not applicable	**Lower** Not applicable	
Explosion Limits	**Upper** Not applicable	**Lower** Not applicable	

10. STABILITY AND REACTIVITY

Chemical Stability Stable at room temperature.

Conditions to Avoid No data available

Materials to Avoid No materials to be especially mentioned.

Hazardous Decomposition Products None under normal use.

Possibility of Hazardous Reactions None under normal use.

11. TOXICOLOGICAL INFORMATION

The following effects are based on the Active Pharmaceutical Ingredient.

Acute Toxicity

Acetaminophen

LD50 Oral	2404 mg/kg rats
Acute Dermal Irritation	No data available
Primary Eye Irritation	No data available
Sensitization	No data available

Acetylsalicylate Acid

LD50 Oral	1460 mg/kg rats, 1100 mg/kg mice, 1010 mg/kg rabbits
Acute Dermal Irritation	7940 mg/kg rabbits, slightly irritating to rabbit skin.
Primary Eye Irritation	Irritating to rabbit eyes.
Sensitization	Not a dermal sensitizer in guinea pigs.

Caffeine

LD50 Oral	192 mg/kg rats, 125 mg/kg mice
Acute Dermal Irritation	> 2000 mg/kg rats
Primary Eye Irritation	Not irritating to rabbit eyes.
Sensitization	No data available

Multiple Dose Toxicity

Acetylsalicylate Acid

No Toxicologic Effect	See Carcinogenicity
Dose/Species/Study Length:	

Caffeine

No Toxicologic Effect	See Carcinogenicity
Dose/Species/Study Length:	

Maximum Tolerated Dose (MTD), Oral

Acetaminophen

Carcinogenicity	Under the conditions of the National Toxicology Program (NTP) studies, there was no evidence of carcinogenic activity in male rats or mice. Equivocal evidence was seen in female rats. IARC Category 3.

Genetic Toxicity	Not mutagenic in AMES Test. Induced sister chromatid exchanges and chromosomal aberrations in cytogenetic tests using Chinese hamster ovary cells.
Reproductive Toxicity	Testicular atrophy and inhibition of spermatogenesis was seen in animal studies at high dose levels. Relevance to humans is not known.
Developmental Toxicity	See Reproductive Toxicity

Acetylsalicylate Acid

Carcinogenicity	Long-term studies in rats revealed no evidence of carcinogenicity.
Genetic Toxicity	AMES Test :Negative- Nonmutagenic Positive in the *in vivo* chromosome aberration assay in cultured fibroblasts.
Reproductive Toxicity	See Developmental Toxicity.
Developmental Toxicity	Fetotoxin and a teratogen in rats, mice, dogs, cats and monkeys at high doses.

Caffeine

Carcinogenicity	In a 2-year study in rats and mice, no evidence of carcinogenic potential was observed.
Genetic Toxicity	Evidence of Genotoxicity was observed in a battery of studies.
Reproductive Toxicity	Studies in monkeys have resulted in reduced fetal weight, stillbirths, and miscarriages.
Developmental Toxicity	Teratogenic effects were reported in both rats and mice at high doses (> 40 mg/kg/day). Digital defects, cleft palate, extra embryonic structures, and urogenital and musculosketal abnormalities were induced. Other findings in animal studies include inhibition of neurogenesis in the mouse embryo; reduced cerebral weight and cardiovascular, lens and thymic changes in rats.

Acetaminophen

Target Organ(s) of Toxicity No data available

Acetylsalicylate Acid

Target Organ(s) of Toxicity No data available

Caffeine

Target Organ(s) of Toxicity No data available

12. ECOLOGICAL INFORMATION

The following effects are based on the Active Pharmaceutical Ingredient.

Chemical Fate Information Not available

Acetaminophen

Mobility	Not available
Biodegradability	Not available
Stability in Water	Not available
Bioaccumulation	Not available

Acetylsalicylate Acid

Mobility	Not available
Biodegradability	Readily biodegradable.
Stability in Water	Not available
Bioaccumulation	Bioaccumulation is unlikely.

Caffeine

Mobility	Not available
Biodegradability	Readily biodegradable.
Stability in Water	Not available
Bioaccumulation	Bioaccumulation is unlikely.

Ecotoxicity Not available

Acetaminophen

Microorganisms	Not available
Algae	Not available
Daphnia	Not available
Fish	Not available

Acetylsalicylate Acid

Microorganisms	Not available
Algae	Not available
Daphnia	EC50/48h/daphnia = 330 mg/l
Fish	Not available

Caffeine

Microorganisms	EC50/17h/bacteria = 3490 mg/l
Algae	EC50/72h/green algae > 100 mg/l
Daphnia	EC50/48h/daphnia = 182 mg/l
Fish	LC50/96h/golden orfe = 87 mg/l

13. DISPOSAL CONSIDERATIONS

Waste Disposal Method Dispose of in accordance with local and national regulations.

14. TRANSPORT INFORMATION

Transport Information This material is not classified as hazardous for transport.

U.S. Department of Transport (DOT)	Not regulated
Canadian Transport of Dangerous Goods (TDG)	Not regulated
International Civil Aviation Organization (ICAO)	Not regulated
International Air Transport Association (IATA)	Not regulated
International Maritime Dangerous Goods (IMDG)/International Maritime Organization (IMO)	Not regulated
Transport of Dangerous Goods by Rail (RID)	Not regulated
Transport of Dangerous Goods by Road (ADR)	Not regulated
Transportation of Dangerous Goods via Inland Waterways (ADN)	Not regulated

15. REGULATORY INFORMATION

USA

Federal Regulations

OSHA Regulatory Status
This material is not considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200)

SARA 313
Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40n of the Code of Federal Regulations, Part 372.

SARA 311/312 Hazardous Categorization

Acute Health Hazard	No
Chronic Health Hazard	No
Fire Hazard	No
Sudden Release of Pressure Hazard	No
Reactive Hazard	No

This product does not contain any HAPs.

State Regulations

California Proposition 65
This product contains the following Proposition 65 chemicals:

Common Name	CAS-No	Type
Acetylsalicylate Acid	50-78-2	Developmental Female Reproductive

Canada

Not classified

WHMIS Hazard Class
Non-controlled

European Union
In accordance with EC directives or respective national laws, the product does not need to be classified nor labeled.

16. OTHER INFORMATION

Prepared By	Wyeth Department of Environment, Health & Safety
Format	This MSDS was prepared in accordance with ANSI Z400.1-2004.
List of References	Product Profiles
Revision Summary	Changes to Section 8

Disclaimer:

The information, data, recommendations, and suggestions appearing in this material safety data sheet (MSDS) and/or in materials regarding our active pharmaceutical ingredients (APIs) or products are based upon tests and data believed to be reliable as of the date of publication. NO REPRESENTATIONS OR WARRANTIES, EITHER EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR ANY OTHER WARRANTY IS MADE WITH REGARD TO THE INFORMATION PROVIDED IN THE MSDS, REGARDING THE API, OR THE PRODUCT TO WHICH THE INFORMATION PERTAINS. Accordingly, Wyeth will not be responsible for any damages resulting from use of, or reliance upon, this information as conditions of use are beyond our control. Users are responsible for assuring the safety of their workers and safe operating conditions, and for determining whether the API or product is suitable for their particular purposes. Users shall assume all risks of their use, handling, and disposal of the API and/or product in accordance with all appropriate and applicable regulations. This information relates only to the API or product designated herein, and does not relate to its use in combination with any other API, material, product, or process. No permission is granted for the use of any API or product in a manner that might infringe on existing patents.

End of MSDS